Yale Howard Bohn

Yale Howard Bohn serves as counsel in the Private Equity group at Goodwin and is a member of the Firm’s Healthcare Private Equity practice. He joined the Firm in 2023.

Yale represents private equity firms, public and private strategic healthcare clients, hospitals, academic medical centers, surgery centers, skilled-nursing and assisted-living facilities, large physician practices and practice management organizations, suppliers, wholesalers and distributors, pharmaceutical companies, group purchasing organizations, and pharmacies, including specialty, long-term care, and 340b contract pharmacies, with respect to transactional, regulatory, and compliance issues.

Yale focuses his practice on healthcare private equity and strategic M&A, and complex federal and state healthcare regulatory matters. He supports private equity and strategic healthcare transactions by: (i) overseeing federal and state healthcare regulatory issues raised by such transactions, including regulatory risk evaluations of targets and acquirors; (ii) addressing compliance and reimbursement issues; and (iii) determining licenses, permits, registrations, and agency notifications triggered by such transactions. In addition, Yale advises clients with respect to non-transactional healthcare regulatory and compliance issues. His specific areas of regulatory expertise include: (i) federal fraud and abuse laws (Anti-Kickback Statute, Stark self-referral prohibition, false claims, civil monetary penalties, etc.) and corresponding state laws; (ii) HIPAA privacy and security; (iii) Medicare Part D (pharmacy benefit plans); (iv) pharmacy licensing; (v) effects of transactions (changes in ownership) on healthcare licensure and registration requirements; and (vi) corporate practice of medicine and fee-splitting.

Representative matters include:

• $1 billion sale of a national long-term care pharmacy chain to a private equity sponsor*
• $750 million equity investment in an outpatient pharmacy management company*
• $500 million acquisition of an inpatient pharmacy management company*
• $500 million acquisition of a national pharmacy*
• $1 billion REIT, skilled nursing facility and assisted living facility acquisitions*
• $500 million recapitalization of specialty and long-term care pharmacies*
• $150 million consolidation and sale of OB/GYN practice management company*
• $100 million sale of a urology practice management company*
• Purchase of dental practice management company*

* Denotes experience prior to joining Goodwin.

• Co-Author, “Additional Disclosure Required: CMS Implements Substantial Changes to Reporting Skilled Nursing Facility Ownership Information,” Goodwin Client Alert, December 1, 2023
• Co-Author, “Cybersecurity Toolkit for Healthcare and Public Health Sector,” Goodwin Client Alert, November 21, 2023
• Co-Author, “California OHCA Publishes Final Regulations Regarding Healthcare Transaction Filing Requirements and Review Process,” Goodwin Client Alert, January 22, 2024